ALLISON DOYLE: Open Payments
NPI 1184309254 · PASADENA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$414 in 13 payments from 7 companies in 2025. Trend: 2023 $26 · 2024 $1,051 · 2025 $414
Food & beverage: $414
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $184 |
| ABBVIE INC. | 4 | $106 |
| Lilly USA, LLC | 1 | $30 |
| Lundbeck LLC | 1 | $29 |
| Alkermes, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
Products named: VRAYLAR, MOUNJARO, VYEPTI, ARISTADA, UBRELVY, Veozah, XIFAXAN, Ozempic.
Industry payments across MD — which companies pay providers there.
